C15ORF39

C15ORF39 (PRMT2IP) is a regulatory protein that couples kinase signaling to control of NF-κB–driven inflammation and, in cancer, to cell cycle progression (PMID:38892217, PMID:40032127). It was first defined biochemically as a phosphosubstrate of the MAPK1/ERK2 kinase (PMID:35044772). C15ORF39 physically associates with the cytoplasmic arginine methyltransferase PRMT2, and this interaction stabilizes IκBα to suppress NF-κB activation, thereby dampening transcription of the inflammatory cytokines IL-6 and TNFα in microglia (PMID:38892217); the same PRMT2–IκBα axis operates for the mouse ortholog, where overexpression reduces and knockout worsens cerebral ischemic injury (PMID:41887540). This suppressive axis is itself under inflammatory control, as activated NF-κBp65 represses the C15ORF39 promoter to form a negative feedback loop (PMID:38892217). In gastric cancer, C15ORF39 is transcriptionally driven by FOXK2 downstream of PI3K/AKT signaling and promotes proliferation, migration, drug resistance, and cell cycle progression, defining a PI3K/AKT/FOXK2/C15ORF39 axis (PMID:40032127).

1. 2022 Medium

   Established the first molecular handle on C15ORF39 by placing it downstream of a specific kinase, answering whether the uncharacterized protein is a regulated signaling node.

   Evidence APEX2 proximity labeling with phospho-enrichment mass spectrometry under kinase ON/OFF conditions in HEK293T and HCT116 cells

   PMID:35044772

   Open questions at the time

   • Phosphosite(s) and functional consequence of MAPK1 phosphorylation not defined
   • No in vitro kinase reconstitution or phosphosite mutagenesis reported
   • Downstream effect of phosphorylation on C15ORF39 activity unknown
2. 2024 Medium

   Identified PRMT2 as a physical partner and defined the IκBα–NF-κB suppressive mechanism, answering what cellular pathway C15ORF39 regulates.

   Evidence Co-IP, gain- and loss-of-function with cytokine and IκBα/NF-κB readouts in HMC3 microglia

   PMID:38892217

   Open questions at the time

   • Whether C15ORF39 affects PRMT2 catalytic activity is not resolved
   • Mechanism by which the interaction stabilizes IκBα unknown
   • Single lab, no reciprocal interaction mapping or structural detail
3. 2024 Low

   Showed the suppressive axis is feedback-regulated, answering how inflammatory signaling overrides C15ORF39's anti-inflammatory function.

   Evidence Promoter activation assay with NF-κBp65 manipulation in LPS/IFN-γ-stimulated HMC3 cells

   PMID:38892217

   Open questions at the time

   • Single method (promoter assay), no direct evidence of p65 binding to the C15ORF39 promoter
   • Endogenous promoter regulatory elements not mapped
   • Kinetics of the feedback loop not characterized
4. 2025 Medium

   Placed C15ORF39 in an oncogenic transcriptional axis, answering how its expression is driven and what proliferative phenotype it produces in cancer.

   Evidence Gain/loss-of-function, FOXK2 promoter-binding assay, cell cycle/migration assays, and sequencing in PIK3CA/B/D knockdown gastric cancer cells

   PMID:40032127

   Open questions at the time

   • Molecular effectors C15ORF39 uses to drive mitosis/cell cycle not identified
   • Whether the PRMT2/NF-κB axis contributes to the cancer phenotype unclear
   • FOXK2 direct binding site on the promoter not finely mapped
5. 2026 Medium

   Provided in vivo genetic validation of the PRMT2–IκBα–NF-κB axis in a disease model, answering whether the mechanism has physiological consequence.

   Evidence Mouse knockout and overexpression in ischemic stroke, Co-IP, NF-κB/IκBα analysis, and Mendelian randomization

   PMID:41887540

   Open questions at the time

   • Cell-type-specific contribution within the brain not dissected
   • Whether MAPK1 phosphorylation modulates the protective effect untested
   • Single lab confirmation of prior in vitro mechanism

• The biochemical activity of C15ORF39 itself — how it stabilizes IκBα, whether MAPK1 phosphorylation gates the PRMT2 interaction, and its molecular role in cell cycle progression — remains undefined.
• No defined enzymatic or structural activity for C15ORF39
• Integration of MAPK1, PRMT2/NF-κB, and PI3K/FOXK2 inputs into one model untested
• No structural data on the C15ORF39–PRMT2 complex